Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).
Last trade$49.74
Day change-$0.07 (-0.14%)
Day range$49.68 – $49.87
Volume1,651,847
Market cap$10.29B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for QGEN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for QGEN.
Recent news
Company coverage with links to the original publishers.
The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.
The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.
Qiagen reported Q3 2026 revenue of $547.87 million, up 2.9% year-over-year, beating consensus estimates by 1.56%. EPS of $0.65 exceeded expectations of $0.63 by 3.18%. Key product segments showed mixed results, with Genomics/NGS and Sample Technologies performing well, while PCR/Nucleic acid amplification and Diagnostic solutions-Other declined. The stock has gained 10.4% over the past month and holds a Zacks Rank #2 (Buy) rating.
Qiagen N.V. (QGEN) is attracting investor attention due to high implied volatility in its December 2026 $55 put options, suggesting traders expect significant price movement. Despite the options market activity, the company maintains a Zacks Rank #2 (Buy) rating with modest analyst estimate increases for the current quarter.
Thailand's NGS market is projected to reach $305.21 million by 2036, growing at a 12.7% CAGR from $92.03 million in 2026. Growth is driven by the Genomics Thailand national precision medicine initiative, rising clinical adoption in oncology and rare diseases, expanded reimbursement under the Universal Coverage Scheme, and increasing demand for outsourced sequencing services. Commercial sequencing services and clinical applications in oncology are expected to be the fastest-growing segments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jul 7, 2026
$0.35
Jul 14, 2026
recurring
Jan 8, 2026
$2.29
—
unknown
Jul 2, 2025
$0.25
Jul 10, 2025
recurring
Jan 29, 2025
$1.26
—
unknown
Jan 25, 2017
$1.1028
—
unknown
Stock splits
Historical share-structure events and their execution dates.